米妥莫單抗
化合物
米妥莫單抗（INN：Mitumomab；開發代號：BEC-2）是一種小鼠抗獨特型（anti-idiotypic）單株抗體，研究用於與卡介苗疫苗聯合治療小細胞肺癌。米妥莫單抗攻擊腫瘤細胞，而卡介苗被認為可以激活免疫系統。米妥莫單抗是由ImClone和默克公司開發的。[1]
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | GD3神經節苷脂 |
| 臨床資料 | |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 216503-58-1  |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
第一個III期臨床試驗於1998年開始。[2][3]2005年和2008年兩次發表的結果顯示，接受米妥莫單抗和卡介苗治療的患者沒有獲益。[4][5]
參見
編輯參考資料
編輯- ^ Mitumomab - AdisInsight. Adisinsight.springer.com. 2005-06-13 [2017-01-06]. （原始內容存檔於2024-03-03）.
- ^ Clinical trial number NCT00037713 for "Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG" at ClinicalTrials.gov
- ^ Clinical trial number NCT00006352 for "Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer" at ClinicalTrials.gov
- ^ Bottomley A, Debruyne C, Felip E, Millward M, Thiberville L, D'Addario G, et al. Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. European Journal of Cancer. October 2008, 44 (15): 2178–84. PMID 18676140. doi:10.1016/j.ejca.2008.06.036.
- ^ Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). Journal of Clinical Oncology. October 2005, 23 (28): 6854–64. PMID 16192577. doi:10.1200/JCO.2005.17.186
.
